Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment resistant depression requiring outpatient ECT~* Planned right unilateral ECT stimulation~* English speaking~* Able to provide written informed consent~Exclusion Criteria:~* Known brain lesion or neurological illness that causes cognitive impairment~* Schizophrenia~* Schizoaffective disorder~* Blindness or deafness or motor impediments that may impair performance for cognitive testing battery~* Inadequate ECT seizure duration with etomidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Etomidate + ECT (Type: ACTIVE_COMPARATOR): General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
- Ketamine + ECT (Type: EXPERIMENTAL): General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
- Ketamine alone (Type: SHAM_COMPARATOR): General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).